Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
Abstract Purpose To investigate the survival outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line novel androgen receptor axis-targeted therapies (ARATs) and prognostic factors for patient survival. Methods This retrospective study obtained data from 202...
Na minha lista:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2023-06-01
|
| coleção: | BMC Cancer |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s12885-023-10885-4 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|